论文部分内容阅读
目的探讨多西他赛治疗晚期乳腺癌患者的临床价值。方法选取2013年5月至2015年5月辽宁省朝阳县人民医院收治的80例晚期乳腺癌患者为研究对象,根据患者自身意愿将其分为对照组与观察组,每组40例。对照组患者采用吉西他滨进行治疗,观察组患者给予多西他赛,比较两组患者近期疗效、生存率及不良反应发生情况。结果观察组患者的近期总好转率明显高于对照组,差异有统计学意义(P<0.05);观察组患者3个月、6个月及1年生存率均明显高于对照组,差异均有统计学意义(均P<0.05);观察组患者不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论为晚期乳腺癌患者实施多西他赛治疗临床疗效显著。
Objective To investigate the clinical value of docetaxel in the treatment of patients with advanced breast cancer. Methods Eighty patients with advanced breast cancer who were treated in Chaoyang County People’s Hospital of Liaoning Province from May 2013 to May 2015 were selected as study subjects and divided into control group and observation group according to patients’ own wishes, 40 cases in each group. Patients in the control group were treated with gemcitabine. Patients in the observation group were given docetaxel, and the short-term efficacy, survival rate and adverse reactions of the two groups were compared. Results The total good turnover rate of the observation group was significantly higher than that of the control group (P <0.05). The 3-month, 6-month and 1-year survival rates of the observation group were significantly higher than those of the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P> 0.05). Conclusion The clinical efficacy of docetaxel in patients with advanced breast cancer is significant.